Skip to content

Parasitic Infection in Anemic Pregnant Women

Parasitic Infection in Anemic Pregnant Women. Prevalence and Effects in Rural Area in Egypt.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04391998
Enrollment
200
Registered
2020-05-18
Start date
2020-05-13
Completion date
2021-09-30
Last updated
2021-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia of Pregnancy

Brief summary

Women included between 18 and 45 years old, pregnant during their second or third trimester of pregnancy (calculated by a sure menstrual date and confirmed by a 1st trimesteric ultrasound) with hemoglobin level below 10.5 mg /dL.

Detailed description

All patients in the study were subjected to: 1. Detailed history was recorded. A proper history concerning age, sex, residence, socioeconomic status, onset, progression, and previous treatment of anemia was taken. Participants' socio-demographic characteristics including gravida and parity were documented, level of education, occupation, Diet, and information useful to determine the socioeconomic level was recorded. Information on previous pregnancies and children and history of chronic diseases were also recorded. 2. General examination; patients were clinically examined and gestational age (assessed by measuring the fundal height), weight was calculated for each participant. 3. Diagnosis of anemia by Complete blood count (CBC), Hb level and measuring hematocrit concentration. 4. Diagnosis of parasitic infection by stool analysis using suitable techniques. 5. Imaging including obstetric ultrasound (U/S) to assess fetal development. 6. Women with helminthic infections will be divided into groups Group (A): received iron + antiparasitic treatment as follows: * Patients who have STH received alzental 200mg tab 2 tabs single oral dose. * Patients who have Entamoeba or Giardia received flagyl 500mg tab twice daily for 5 days. * (B): received iron only.

Interventions

oral tablet twice daily after meals

500 mg oral twice daily

DRUGAlbendazole

200 mg oral single dose

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* pregnant during their second or third trimester of pregnancy (calculated by a sure menstrual date and confirmed by a 1st trimesteric ultrasound) * hemoglobin level below 10.5 mg /dL

Exclusion criteria

* women with chronic diseases as diabetes, heart, renal, hepatic or endocrinological disorders * women diagnosed with blood diseases as hemoglobinopathy or vascular diseases as vasculitis. * Women with autoimmune diseases and those allergic to iron or antihelminsic treatment were also excluded

Design outcomes

Primary

MeasureTime frameDescription
correction of naemia6 weeks after treatmenthemoglobin level increased above 11 gm/dL

Countries

Egypt

Contacts

Primary ContactAhmed maged, MD
prof.ahmedmaged@gmail.com+201005227404
Backup ContactWesam deeb, MD
wesameldeeb@yahoo.com+201066302616

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026